Will Melanotan II become legal? The PCAC review

By The Docket DeskResearched & sourcedUpdated 17 Oct 2026

The short answer

The FDA’s Pharmacy Compounding Advisory Committee is due to review Melanotan II before the end of February 2027. It is currently not FDA-approved and not legal to compound; the vote is the first formal step toward potential legal compounding.

FDA approvalNot approved

Compounding statusRemoved from Category 2 (Apr 2026, nominations withdrawn) · not on Category 1 — compounding not authorized

Under FDA reviewPCAC · before end of Feb 2027

Use under reviewTanning

Earliest pharmacy accessLate 2027 at the earliest (if cleared)

A committee “yes” is a recommendation, not legalization. The path has two stages: first the PCAC vote, then formal FDA rulemaking. Each peptide effectively turns on both — which is why a favorable vote still doesn’t mean you can fill a prescription the next day.

What happens before the end of February 2027

The FDA’s Pharmacy Compounding Advisory Committee will hear evidence and vote on whether Melanotan II should be added to the 503A list for tanning. A “yes” is a recommendation only; the FDA would then need to issue a final rule before any pharmacy could legally compound it. Realistic patient access, if it happens at all, is late 2027 at the earliest: the committee is not due to review it until February 2027, and FDA rulemaking follows any recommendation.

Will Melanotan II become legal in 2026?+

Not automatically. The committee meets before end of Feb 2027; a favorable vote is a recommendation only — the FDA must then issue a final rule, which typically takes months. Realistic legal compounded access is late 2027 at the earliest, and only if both steps go through.

Is “research-grade” Melanotan II the same as a medicine?+

No. Material sold “for research use only” is not made or tested to pharmaceutical standards, is not authorized for human use, and carries no guarantee of identity, purity or sterility. This site does not link to or evaluate these sellers.

Primary sources: FDA 503A interim list (Apr 2026 update) · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.

Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. Melanotan II is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.